0.90Open0.90Pre Close0 Volume26 Open Interest400.00Strike Price0.00Turnover151.48%IV71.12%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type0.0379Delta0.0013Gamma260.31Leverage Ratio-0.2068Theta0.0027Rho9.87Eff Leverage0.0356Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet